Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Neostigmine
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection
Details : Neostigmine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Intestinal Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 01, 2023
Lead Product(s) : Neostigmine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable